CCO Independent Conference Coverage
|
|
2010 American Society of Clinical Oncology Annual Meeting*
June 4-8, 2010 | Chicago, Illinois
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Choose from 7 tracks of coverage (mouse over track for more info)
|
Expert Highlights
 |
Thomas J. Herzog, MD, highlights the most compelling data in ovarian cancer including those of the phase III GOG 218 trial. (8 minutes) |
 |
Download Audio |
 |
Keith T. Flaherty, MD, reviews a landmark phase III study investigating ipilimumab in patients with previously treated, unresectable stage III or IV melanoma. (4 minutes) |
|
Download Audio |
 |
Kathy D. Miller, MD, reviews highlights from the 2010 American Society of Clinical Oncology Annual Meeting including discussion of the EMBRACE, NSABP B-32, ACOSOG Z0010, and ACOSOG Z0011 studies. (7 minutes) |
|
Download Audio |
 |
James O. Armitage, MD, reviews key studies and new clinically relevant developments in the treatment of lymphoma. (5 minutes) |
|
Download Audio |
 |
Thomas H. Cartwright, MD, summarizes important abstracts in gastrointestinal cancers including the use of biomarkers in selecting therapy for patients with colorectal cancers and important findings from trials in advanced pancreatic cancer. (2 minutes) |
|
Download Audio |
 |
Nicholas J. Vogelzang, MD, discusses the clinical relevance of several studies on genitourinary cancers presented at the 2010 American Society of Clinical Oncology Annual Meeting. (12 minutes) |
|
Download Audio |
Disclosures – Audio Expert Highlights
Thomas J. Herzog, MD, has disclosed that he has received consulting fees from Amgen, Genentech, GlaxoSmithKline, Johnson & Johnson, Pfizer, and sanofi-aventis and fees for non-CME services from Amgen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Merck, and Precision Therapeutics.
Keith T. Flaherty, MD, has disclosed that he has received consulting fees from GlaxoSmithKline and Roche.
Kathy D. Miller, MD, has disclosed that she has received contracted research from Amgen, Genentech, Geron, and Pfizer; had received consulting fees from Genentech, MethylGene, and Roche; and has received fees for non-CME services from Genentech and Roche.
James O. Armitage, MD, has disclosed that he has received consulting fees from Allos Therapeutics, Biogen Idec, Eisai, Seattle Genetics, and Ziopharm.
Thomas H. Cartwright, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, and Genentech and fees for non-CME services from Amgen, Bristol-Myers Squibb, Eli Lilly and Company, and Genentech.
Nicholas J. Vogelzang, MD, has no significant financial relationships to disclose.
CCO Slidesets
Breast Cancer
 |
|
In this downloadable slideset, Stephen E. Jones, MD reviews key data in early and metastatic breast cancer presented at the 2010 American Society of Clinical Oncology Annual Meeting.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.85 MB
| Date posted: 6/23/2010
|
Hematologic Malignancies
 |
|
In this downloadable slideset, Nicholas J. DiBella, MD, highlights key lymphoma, chronic myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma clinical trial data presented at the 2010 American Society of Clinical Oncology Annual Meeting.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.43 MB
| Date posted: 6/28/2010
|
Gastrointestinal Cancer
 |
|
In this downloadable slideset, Thomas H. Cartwright, MD highlights key data in the settings of colorectal, pancreatic, and gastric cancers presented at the 2010 American Society of Clinical Oncology Annual Meeting.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.40 MB
| Date posted: 6/18/2010
|
Genitourinary Cancer
 |
|
In this downloadable slideset, Nicholas J. Vogelzang, MD reviews key data in prostate cancer and renal cell carcinoma presented at the 2010 American Society of Clinical Oncology Annual Meeting.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.26 MB
| Date posted: 6/24/2010
|
|
Jointly sponsored by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Capsule Summary:
Novel Bcr-Abl Inhibitor Bosutinib Safe and Active in Imatinib-Resistant/Intolerant CML
In this phase I/II trial, bosutinib treatment was associated with a 91% rate of complete hematologic response, a 50% rate of complete cytogenetic response, and a 52% rate of major molecular response; 19% of patients discontinued treatment because of toxicity.
CLICK HERE TO KEEP READING
CLICK HERE FOR RELATED CAPSULE SUMMARIES
|